Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 20/20 | 0.67 |
| ▸ | ICAM1 | P05362 | 20/20 | 0.67 |
| ▸ | ITGAL | P20701 | 20/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13658126 | 0.90 | ITGAL (0.70) | ITGB2ICAM1ITGAL | |
| SCHEMBL13667754 | 0.87 | ITGB2 (0.52) | ITGB2ICAM1ITGAL | |
| SCHEMBL23153575 | 0.82 | ITGB2 (0.60) | ITGB2ICAM1ITGAL | |
| SCHEMBL13658127 | 0.80 | ITGB2 (1.00) | ITGB2ICAM1ITGAL | |
| SCHEMBL13665668 | 0.78 | ITGB2 (0.55) | ITGB2ICAM1ITGAL | |
| SCHEMBL15480500 | 0.78 | ITGB2 (0.48) | ITGB2ICAM1ITGAL | |
| SCHEMBL13813602 | 0.73 | ITGB2 (0.86) | ITGB2ICAM1ITGAL | |
| SCHEMBL23992600 | 0.73 | ITGB2 (0.85) | ITGB2ICAM1ITGAL | |
| SCHEMBL23978604 | 0.71 | ITGB2 (0.74) | ITGB2ICAM1ITGAL | |
| SCHEMBL23978571 | 0.71 | ITGB2 (0.74) | ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051722-A1 | TOPICAL LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS | SARCODE BIOSCIENCE INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051722-A1 | TOPICAL LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS | SARCODE BIOSCIENCE INC. (US) | 2014-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051722-A1 | TOPICAL LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS | VCAM1, ICAM1, CD69 | ITGB2 10/4885ICAM1 2/4885ITGAL 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.